Sign inJoin waitlistJoin the waitlist

Janice Mehnert

Director, Melanoma Medical Oncology Program · NYU Grossman School of Medicine

Credentials: · · · · ·

History

Yale-New Haven Hospital
2005–2007
Internal Medicine
Mount Sinai Hospital
2001–2004
Robert Wood Johnson Medical School
1997–2001

Research

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20…
Journal of Clinical Oncology · 2019 · 767 citations
Autophagy, Metabolism, and Cancer
Review · Clinical Cancer Research · 2015 · 559 citations
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
JAMA Oncology · 2016 · 537 citations

Ann Silk
17 papers
Mark Stein
16 papers
HK
Howard Kaufman
14 papers
Ryan Sullivan
13 papers · 2 as a fellow
JM
Jyoti Malhotra
12 papers
Igor Puzanov
11 papers
Kristen Spencer
11 papers · 6 as a resident
Shridar Ganesan
11 papers
Douglas Johnson
10 papers
IO
Iman Osman
9 papers
JA
Joseph Aisner
9 papers
Nancy Chan
8 papers

Grants

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $1.2M · New York University School of Medicine
1996–2029
K12 Training for Clinical and Translational Oncology Researchers
National Cancer Institute · K12
Contact PI · $1.6M · New York University School of Medicine
2023–2028
“Promoting a Culture Of Innovation, Mentorship, and Clinical Investigation in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D
National Cancer Institute · R50
Contact PI · $442.8K · New York University School of Medicine
2023–2028
Correlative Biomarkers of IL-6 Blockade Combined with Checkpoint Inhibition
National Cancer Institute · R01
Contact PI · $563.7K · New York University School of Medicine
2020–2026

Clinical trials

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
Principal investigator · Recruiting · Phase 2
NYU Langone Health
2026–2031
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Principal investigator · Recruiting · Phase 2
NYU Langone Health
2023–2028
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Principal investigator · Active not recruiting · Phase 2
NYU Langone Health
2019–2030
Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial
Principal investigator · Active not recruiting · Phase 3
National Cancer Institute (NCI)
2018–2026